{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:22:58Z","timestamp":1761585778199,"version":"build-2065373602"},"posted":{"date-parts":[[2025,5,14]]},"group-title":"In Review","reference-count":55,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,5,1]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Histone deacetylase inhibitors (HDACis) are promising anti-cancer agents but remain underexplored in glioblastoma (GBM). This study evaluated the effects of three HDACis\u2014CAY10603, vorinostat (SAHA), and valproic acid (VPA)\u2014on human GBM cell lines (U87, MGG8) with immortalized human astrocytes (IHAs) as healthy controls. HDACis were tested alone or in combination with temozolomide (TMZ), the standard chemotherapy for GBM, in both 2D (monolayer) and 3D (neurosphere) cultures. Additionally, co-culture of GBM cells with macrophages (M0, biochemically differentiated from THP-1 human monocytes) was used to examine the impact of HDACis on cancer-immune interactions. Results demonstrated that all three HDACis significantly reduced cell viability and synergistically enhanced the effect of TMZ. CAY10603 and SAHA induced early apoptosis and upregulated caspase 3 (CASP3) expression, whereas VPA primarily induced late apoptosis and necrosis in GBM cultures. VPA induced both G0\/G1 and G2\/M cell cycle arrest, while SAHA and CAY10603 only induced G2\/M arrest. mRNA expression analysis following HDACi treatment in U87 neurospheres revealed that HDACis inhibited expression of markers for epithelial-to-mesenchymal transition (EMT), proliferation, and stemness pathways. In U87-M0 co-cultures, we observed significant upregulation of stemness markers and the pro-inflammatory cytokine TNF-\u03b1 following CAY10603 and VPA treatments. In contrast, TMZ monotherapy upregulated the expression of the immunosuppressive cytokine TGF-\u03b2. These findings suggest that HDAC inhibition\u2014including the novel small molecule CAY10603\u2014sensitizes GBM to temozolomide and confers potent anti-tumor effects that combat GBM (e.g., reducing proliferation, EMT, stemness). Our\n                  <italic>in vitro<\/italic>\n                  findings \u2014e.g., with 3D neurospheres that better mimic physiological tumor growth than 2D monolayers\u2014warrant future\n                  <italic>in vivo<\/italic>\n                  testing of HDACis alone or in combination with chemotherapy.\n                <\/p>","DOI":"10.21203\/rs.3.rs-6573675\/v1","type":"posted-content","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:16:09Z","timestamp":1747192569000},"source":"Crossref","is-referenced-by-count":0,"title":["Histone deacetylase inhibitors sensitize glioblastoma models to temozolomide and reprogram immunosuppressive myeloid cells"],"prefix":"10.21203","author":[{"given":"Golnaz Asaadi","family":"Tehrani","sequence":"first","affiliation":[{"name":"University of Notre Dame"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Becca","family":"Kubick","sequence":"additional","affiliation":[{"name":"University of Notre Dame"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maksym","family":"Zarodniuk","sequence":"additional","affiliation":[{"name":"University of Notre Dame"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meenal","family":"Datta","sequence":"additional","affiliation":[{"name":"University of Notre Dame"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fonc.2016.00016","article-title":"Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation","volume":"6","author":"Liu A","year":"2016","unstructured":"Liu, A., Hou, C., Chen, H., Zong, X. & Zong, P. Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation. Front. Oncol. 6, 16. https:\/\/doi.org\/10.3389\/fonc.2016.00016 (2016).","journal-title":"Front. Oncol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.semcancer.2020.12.015","article-title":"Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches","volume":"83","author":"Uddin MS","year":"2022","unstructured":"Uddin, M. S. et al. Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches. Sem. Cancer Biol. 83, 100\u2013120. 10.1016\/j.semcancer.2020.12.015 (2022). https:\/\/doi.org\/https:\/\/doi.org\/","journal-title":"Sem. Cancer Biol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3389\/fonc.2018.00448","article-title":"Epigenetic Targeting of Glioblastoma","volume":"8","author":"Romani M","year":"2018","unstructured":"Romani, M., Pistillo, M. P. & Banelli, B. Epigenetic Targeting of Glioblastoma. Front. Oncol. 8, 448. https:\/\/doi.org\/10.3389\/fonc.2018.00448 (2018).","journal-title":"Front. Oncol."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/diseases7040057","article-title":"Histone Deacetylases and their Inhibitors in Cancer Epigenetics","volume":"7","author":"Hassell KN","year":"2019","unstructured":"Hassell, K. N. Histone Deacetylases and their Inhibitors in Cancer Epigenetics. Diseases 7 https:\/\/doi.org\/10.3390\/diseases7040057 (2019).","journal-title":"Diseases"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.576946","article-title":"The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy","volume":"8","author":"Li G","year":"2020","unstructured":"Li, G., Tian, Y. & Zhu, W. G. The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy. Front. Cell. Dev. Biology. 8 https:\/\/doi.org\/10.3389\/fcell.2020.576946 (2020).","journal-title":"Front. Cell. Dev. Biology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights","volume":"143","author":"Bose P","year":"2014","unstructured":"Bose, P., Dai, Y. & Grant, S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol. Ther. 143, 323\u2013336. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.04.004 (2014).","journal-title":"Pharmacol. Ther."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"14639","DOI":"10.1073\/pnas.1008522107","article-title":"Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair","volume":"107","author":"Lee JH","year":"2010","unstructured":"Lee, J. H., Choy, M. L., Ngo, L., Foster, S. S. & Marks, P. A. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc. Natl. Acad. Sci. U S A. 107, 14639\u201314644. https:\/\/doi.org\/10.1073\/pnas.1008522107 (2010).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e1435","DOI":"10.1038\/cddis.2014.412","article-title":"Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe","volume":"5","author":"Cornago M","year":"2014","unstructured":"Cornago, M. et al. Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. Cell Death Dis. 5, e1435\u2013e1435. https:\/\/doi.org\/10.1038\/cddis.2014.412 (2014).","journal-title":"Cell Death Dis."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.canlet.2008.03.037","article-title":"Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy","volume":"269","author":"Carew JS","year":"2008","unstructured":"Carew, J. S., Giles, F. J. & Nawrocki, S. T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 269, 7\u201317. https:\/\/doi.org\/10.1016\/j.canlet.2008.03.037 (2008).","journal-title":"Cancer Lett."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s12032-014-0985-5","article-title":"Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience","volume":"31","author":"Bezecny P","year":"2014","unstructured":"Bezecny, P. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience. Med. Oncol. 31, 985. https:\/\/doi.org\/10.1007\/s12032-014-0985-5 (2014).","journal-title":"Med. Oncol."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167081","article-title":"Quisinostat is a brain-penetrant radiosensitizer in glioblastoma","volume":"8","author":"Lo Cascio C","year":"2023","unstructured":"Lo Cascio, C. et al. Quisinostat is a brain-penetrant radiosensitizer in glioblastoma. JCI Insight. 8 https:\/\/doi.org\/10.1172\/jci.insight.167081 (2023).","journal-title":"JCI Insight"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal M","year":"2015","unstructured":"Mottamal, M., Zheng, S., Huang, T. L. & Wang, G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 20, 3898\u20133941. https:\/\/doi.org\/10.3390\/molecules20033898 (2015).","journal-title":"Molecules"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyz218","author":"Sanai N","year":"2019","unstructured":"Sanai, N. Phase 0 Clinical Trial Strategies for the Neurosurgical Oncologist. Neurosurgery 85, E967-e974 (2019). https:\/\/doi.org\/10.1093\/neuros\/nyz218"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13046-020-01643-6","article-title":"The application of histone deacetylases inhibitors in glioblastoma","volume":"39","author":"Chen R","year":"2020","unstructured":"Chen, R. et al. The application of histone deacetylases inhibitors in glioblastoma. J. Exp. Clin. Cancer Res. 39, 138. https:\/\/doi.org\/10.1186\/s13046-020-01643-6 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref15","first-page":"166","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim HJ","year":"2011","unstructured":"Kim, H. J. & Bae, S. C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl Res. 3, 166\u2013179 (2011).","journal-title":"Am. J. Transl Res."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in targeting histone deacetylase for treatment of solid tumors","volume":"17","author":"Shi MQ","year":"2024","unstructured":"Shi, M. Q. et al. Advances in targeting histone deacetylase for treatment of solid tumors. J. Hematol. Oncol. 17, 37. https:\/\/doi.org\/10.1186\/s13045-024-01551-8 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: Trends and challenges","volume":"13","author":"Liang T","year":"2023","unstructured":"Liang, T. et al. Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharm. Sin B. 13, 2425\u20132463. https:\/\/doi.org\/10.1016\/j.apsb.2023.02.007 (2023).","journal-title":"Acta Pharm. Sin B"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.bpj.2024.03.034","article-title":"Single-cell mechanical assay unveils viscoelastic similarities in normal and neoplastic brain cells","volume":"123","author":"Onwudiwe K","year":"2024","unstructured":"Onwudiwe, K. et al. Single-cell mechanical assay unveils viscoelastic similarities in normal and neoplastic brain cells. Biophys. J. 123, 1098\u20131105. https:\/\/doi.org\/10.1016\/j.bpj.2024.03.034 (2024).","journal-title":"Biophys. J."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41551-018-0334-7","article-title":"Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium","volume":"3","author":"Seano G","year":"2019","unstructured":"Seano, G. et al. Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. Nat. Biomed. Eng. 3, 230\u2013245. https:\/\/doi.org\/10.1038\/s41551-018-0334-7 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak KJ","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262 (2001).","journal-title":"Methods"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"11239","DOI":"10.18632\/oncotarget.14496","article-title":"Activation of TRPM7 by naltriben enhances migration and invasion of glioblastoma cells","volume":"8","author":"Wong R","year":"2017","unstructured":"Wong, R., Turlova, E., Feng, Z. P., Rutka, J. T. & Sun, H. S. Activation of TRPM7 by naltriben enhances migration and invasion of glioblastoma cells. Oncotarget 8, 11239\u201311248. https:\/\/doi.org\/10.18632\/oncotarget.14496 (2017).","journal-title":"Oncotarget"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"102307","DOI":"10.1016\/j.ceca.2020.102307","article-title":"Inhibition of TRPM7 with waixenicin A reduces glioblastoma cellular functions","volume":"92","author":"Wong R","year":"2020","unstructured":"Wong, R. et al. Inhibition of TRPM7 with waixenicin A reduces glioblastoma cellular functions. Cell. Calcium. 92, 102307. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.ceca.2020.102307 (2020).","journal-title":"Cell. Calcium"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"16321","DOI":"10.18632\/oncotarget.3872","article-title":"Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell proliferation, migration and invasion","volume":"6","author":"Chen WL","year":"2015","unstructured":"Chen, W. L. et al. Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell proliferation, migration and invasion. Oncotarget 6, 16321\u201316340. https:\/\/doi.org\/10.18632\/oncotarget.3872 (2015).","journal-title":"Oncotarget"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010018","article-title":"Myeloid Cells in Glioblastoma Microenvironment","volume":"10","author":"Leo A","year":"2020","unstructured":"De Leo, A., Ugolini, A. & Veglia, F. Myeloid Cells in Glioblastoma Microenvironment. Cells 10 https:\/\/doi.org\/10.3390\/cells10010018 (2020).","journal-title":"Cells"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"9123","DOI":"10.18632\/oncotarget.13265","article-title":"A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma","volume":"8","author":"Choi SA","year":"2017","unstructured":"Choi, S. A. et al. A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma. Oncotarget 8, 9123\u20139133. https:\/\/doi.org\/10.18632\/oncotarget.13265 (2017).","journal-title":"Oncotarget"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1002\/cncr.34974","article-title":"Recent histone deacetylase inhibitors in cancer therapy","volume":"129","author":"Parveen R","year":"2023","unstructured":"Parveen, R., Harihar, D. & Chatterji, B. P. Recent histone deacetylase inhibitors in cancer therapy. Cancer 129, 3372\u20133380. https:\/\/doi.org\/10.1002\/cncr.34974 (2023).","journal-title":"Cancer"},{"key":"ref27","first-page":"615","article-title":"Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy","volume":"35","author":"Lee P","year":"2015","unstructured":"Lee, P. et al. Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy. Anticancer Res. 35, 615\u2013625 (2015).","journal-title":"Anticancer Res."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.4161\/auto.25664","article-title":"Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells","volume":"9","author":"Chiao MT","year":"2013","unstructured":"Chiao, M. T., Cheng, W. Y., Yang, Y. C., Shen, C. C. & Ko, J. L. Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells. Autophagy 9, 1509\u20131526. https:\/\/doi.org\/10.4161\/auto.25664 (2013).","journal-title":"Autophagy"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"722754","DOI":"10.3389\/fonc.2021.722754","article-title":"Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53-PUMA Apoptosis Pathway","volume":"11","author":"Tsai HC","year":"2021","unstructured":"Tsai, H. C. et al. Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53-PUMA Apoptosis Pathway. Front. Oncol. 11, 722754. https:\/\/doi.org\/10.3389\/fonc.2021.722754 (2021).","journal-title":"Front. Oncol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","article-title":"Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma","volume":"16","author":"Duvic M","year":"2007","unstructured":"Duvic, M. & Vu, J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin. Investig. Drugs. 16, 1111\u20131120. https:\/\/doi.org\/10.1517\/13543784.16.7.1111 (2007).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/neuonc\/nox161","article-title":"Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874\/ABTC 02","volume":"20","author":"Galanis E","year":"2018","unstructured":"Galanis, E. et al. Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874\/ABTC 02. Neuro Oncol. 20, 546\u2013556. https:\/\/doi.org\/10.1093\/neuonc\/nox161 (2018).","journal-title":"Neuro Oncol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1200\/jco.2008.19.0694","article-title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study","volume":"27","author":"Galanis E","year":"2009","unstructured":"Galanis, E. et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J. Clin. Oncol. 27, 2052\u20132058. https:\/\/doi.org\/10.1200\/jco.2008.19.0694 (2009).","journal-title":"J. Clin. Oncol."},{"key":"ref33","article-title":"Vorinostat(SAHA) Promotes Hyper-Radiosensitivity in Wild Type p53 Human Glioblastoma Cells","volume":"2","author":"Diss E","year":"2014","unstructured":"Diss, E. et al. Vorinostat(SAHA) Promotes Hyper-Radiosensitivity in Wild Type p53 Human Glioblastoma Cells. J. Clin. Oncol. Res. 2 (2014).","journal-title":"J. Clin. Oncol. Res."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1177\/10600280211055508","article-title":"Valproic Acid After Neurosurgery Induces Elevated Risk of Liver Injury: A Prospective Nested Case-Control Study","volume":"56","author":"Guo J","year":"2022","unstructured":"Guo, J. et al. Valproic Acid After Neurosurgery Induces Elevated Risk of Liver Injury: A Prospective Nested Case-Control Study. Ann. Pharmacother. 56, 888\u2013897. https:\/\/doi.org\/10.1177\/10600280211055508 (2022).","journal-title":"Ann. Pharmacother"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"14666","DOI":"10.18632\/oncotarget.14716","article-title":"Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression","volume":"8","author":"Tseng JH","year":"2017","unstructured":"Tseng, J. H. et al. Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression. Oncotarget 8, 14666\u201314679. https:\/\/doi.org\/10.18632\/oncotarget.14716 (2017).","journal-title":"Oncotarget"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"35004","DOI":"10.18632\/oncotarget.5253","article-title":"Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells","volume":"6","author":"Thotala D","year":"2015","unstructured":"Thotala, D. et al. Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells. Oncotarget 6, 35004\u201335022. https:\/\/doi.org\/10.18632\/oncotarget.5253 (2015).","journal-title":"Oncotarget"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41419-020-2586-x","article-title":"Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma","volume":"11","author":"Auzmendi-Iriarte J","year":"2020","unstructured":"Auzmendi-Iriarte, J. et al. Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma. Cell Death Dis. 11, 417. https:\/\/doi.org\/10.1038\/s41419-020-2586-x (2020).","journal-title":"Cell Death Dis."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33889-3","article-title":"HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma","volume":"13","author":"Garrett M","year":"2023","unstructured":"Garrett, M. et al. HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma. Sci. Rep. 13 https:\/\/doi.org\/10.1038\/s41598-023-33889-3 (2023).","journal-title":"Sci. Rep."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.canlet.2016.06.001","article-title":"HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma","volume":"379","author":"Wang Z","year":"2016","unstructured":"Wang, Z. et al. HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma. Cancer Lett. 379, 134\u2013142. https:\/\/doi.org\/10.1016\/j.canlet.2016.06.001 (2016).","journal-title":"Cancer Lett."},{"year":"2024","author":"Spallotta F","key":"ref40","unstructured":"Spallotta, F. & Illi, B. The Role of HDAC6 in Glioblastoma Multiforme: A New Avenue to Therapeutic Interventions? Biomedicines 12 (2024)."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"216121","DOI":"10.1016\/j.canlet.2023.216121","article-title":"The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy","volume":"559","author":"Moran B","year":"2023","unstructured":"Moran, B., Davern, M., Reynolds, J. V., Donlon, N. E. & Lysaght, J. The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy. Cancer Lett. 559, 216121. https:\/\/doi.org\/10.1016\/j.canlet.2023.216121 (2023).","journal-title":"Cancer Lett."},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC Inhibitors in Cancer Development and Therapy","volume":"6","author":"Li Y","year":"2016","unstructured":"Li, Y. & Seto, E. HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect. Med. 6 https:\/\/doi.org\/10.1101\/cshperspect.a026831 (2016).","journal-title":"Cold Spring Harb Perspect. Med."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/genes12020260","article-title":"Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2\/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells","author":"Hoffmann MJ","year":"2021","unstructured":"Hoffmann, M. J., Meneceur, S., Hommel, K., Schulz, W. A. & Niegisch, G. Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2\/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells. Genes (Basel). 12. https:\/\/doi.org\/10.3390\/genes12020260 (2021).","journal-title":"Genes (Basel)"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/1078-0432.ccr-03-0100","article-title":"Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells","volume":"10","author":"Takai N","year":"2004","unstructured":"Takai, N. et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin. Cancer Res. 10, 1141\u20131149. https:\/\/doi.org\/10.1158\/1078-0432.ccr-03-0100 (2004).","journal-title":"Clin. Cancer Res."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18091883","article-title":"Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53","volume":"18","author":"Mrakovcic M","year":"2017","unstructured":"Mrakovcic, M., Kleinheinz, J. & Fr\u00f6hlich, L. F. Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53. Int. J. Mol. Sci. 18 https:\/\/doi.org\/10.3390\/ijms18091883 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1161\/circulationaha.112.103176","article-title":"Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid","volume":"126","author":"Zhao L","year":"2012","unstructured":"Zhao, L. et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 126, 455\u2013467. https:\/\/doi.org\/10.1161\/circulationaha.112.103176 (2012).","journal-title":"Circulation"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1177\/2472555218775055","article-title":"A Cytotoxic Three-Dimensional-Spheroid, High-Throughput Assay Using Patient-Derived Glioma Stem Cells","volume":"23","author":"Quereda V","year":"2018","unstructured":"Quereda, V. et al. A Cytotoxic Three-Dimensional-Spheroid, High-Throughput Assay Using Patient-Derived Glioma Stem Cells. SLAS Discov. 23, 842\u2013849. https:\/\/doi.org\/10.1177\/2472555218775055 (2018).","journal-title":"SLAS Discov"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1158\/1078-0432.Ccr-17-2256","article-title":"Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models","volume":"24","author":"Kogiso M","year":"2018","unstructured":"Kogiso, M. et al. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models. Clin. Cancer Res. 24, 2159\u20132170. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2256 (2018).","journal-title":"Clin. Cancer Res."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11060-019-03107-0","article-title":"A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia","volume":"142","author":"Musah-Eroje A","year":"2019","unstructured":"Musah-Eroje, A. & Watson, S. A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia. J. Neurooncol. 142, 231\u2013240. https:\/\/doi.org\/10.1007\/s11060-019-03107-0 (2019).","journal-title":"J. Neurooncol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1525360113","author":"Kloepper J","year":"2016","unstructured":"Kloepper, J. et al. Ang-2\/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proceedings of the National Academy of Sciences 113, 4476\u20134481 (2016). https:\/\/doi.org\/10.1073\/pnas.1525360113"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1525349113","author":"Peterson TE","year":"2016","unstructured":"Peterson, T. E. et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proceedings of the National Academy of Sciences 113, 4470\u20134475 (2016). https:\/\/doi.org\/10.1073\/pnas.1525349113"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1172\/jci163446","article-title":"Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy","volume":"133","author":"Khan F","year":"2023","unstructured":"Khan, F. et al. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. J. Clin. Invest. 133 https:\/\/doi.org\/10.1172\/jci163446 (2023).","journal-title":"J. Clin. Invest."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"19542","DOI":"10.1038\/s41598-020-76657-3","article-title":"Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma","volume":"10","author":"Landry AP","year":"2020","unstructured":"Landry, A. P., Balas, M., Alli, S., Spears, J. & Zador, Z. Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma. Sci. Rep. 10, 19542. https:\/\/doi.org\/10.1038\/s41598-020-76657-3 (2020).","journal-title":"Sci. Rep."},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2219199120","author":"Datta M","year":"2023","unstructured":"Datta, M. et al. Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models. Proceedings of the National Academy of Sciences 120, e2219199120 (2023). https:\/\/doi.org\/10.1073\/pnas.2219199120"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12195-024-00824-z","article-title":"Novel 3-D Macrophage Spheroid Model Reveals Reciprocal Regulation of Immunomechanical Stress and Mechano-Immunological Response","volume":"17","author":"Burchett A","year":"2024","unstructured":"Burchett, A., Siri, S., Li, J., Lu, X. & Datta, M. Novel 3-D Macrophage Spheroid Model Reveals Reciprocal Regulation of Immunomechanical Stress and Mechano-Immunological Response. Cell. Mol. Bioeng. 17, 329\u2013344. https:\/\/doi.org\/10.1007\/s12195-024-00824-z (2024).","journal-title":"Cell. Mol. Bioeng."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6573675\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6573675\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:13:50Z","timestamp":1761585230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6573675\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":55,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-6573675\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41598-025-20749-5","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,5,14]]},"subtype":"preprint"}}